NEW YORK – Bio-Techne on Tuesday announced that its fiscal 2021 second quarter revenues rose 21 percent year over year.
For the three months ended Dec. 31, 2020, the Minneapolis-based firm reported $224.3 million in revenues, up from $184.9 million a year ago and beating analysts' average estimate of $206.5 million.
In Q2, the firm reported Diagnostics and Genomics revenue of $52.5 million, up 20 percent year over year from $43.8 million, and Protein Sciences revenue of $172.2 million, up 22 percent from $141.5 million in the prior-year quarter.